Acarix AB (publ) (STO:ACARIX)
Sweden
· Delayed Price · Currency is SEK 0.2400
-0.0010 (-0.41%)
Jun 5, 2025, 5:29 PM CET
Acarix AB Company Description
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out.
The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow.
It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States.
The company was founded in 2009 and is headquartered in Malmö, Sweden.
Acarix AB (publ)
| Country | Sweden |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Aamir Mahmood |
Contact Details
Address: Regus MalmOe Malmö, 215 32 Sweden | |
| Website | acarix.com |
Stock Details
| Ticker Symbol | ACARIX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009268717 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Aamir Mahmood | President and Chief Executive Officer |
| Christian Lindholm | Chief Financial Officer and Executive Vice President |
| Carma Connely | Head of Operations and Customer Excellence |
| Jennifer Matson | Head of Medical Affairs |
| Jeff Thomas | Head of US Sales |
| Dwyndl Nelms | Head of QA, RA and Production |
| Dr. George Chrysant M.D. | Chief Medical Advisor |
| Daniel Burke | Head of Reimbursement and Market Access |
| Jeffrey Rudd | Head of US Finance |